The course, Cancer Immunity & Immunotherapy, will review tumor immunology as the scientific foundation for the current practice of cancer immunotherapy, emphasizing fundamental principles, recent clinical advances, current limitations, and near-term opportunities for further accelerating clinical progress.
After the course, attendees will be able to:
- Describe mechanisms of the immune response against cancer cells and how these responses are regulated during cancer development and progression.
- Describe the principles underlying chimeric antigen receptor transduced T cells (CAR-T cells) and T cell receptor (TCR)-transduced T cells and their efficacy in the treatment of leukemias and other cancers.
- Appreciate the potential opportunities and limitations of utilizing CAR-T cells for treating solid tumors and understand the development of second-generation CARs.
- Understand the biology of immune checkpoint pathways and checkpoint blockade therapy for solid tumors, the development of biomarkers to predict therapeutic responses, and the potential for combination therapies.
- Describe the unique adverse event profile associated with immune checkpoint blockade and CAR-T cell therapy, and clinical strategies for managing those immune-related toxicities.
- Understand the potential of emerging strategies for cancer immunotherapy.
2022 Course Faculty
Abul Abbas, MD, University of California, San Francisco
Lisa Butterfield, PhD, Parker Institute for Cancer
Michelle Hermiston, MD, PhD, University of California, San Francisco
Daniel Powell, PhD, University of Pennsylvania (Course Director)
Kole Roybal, PhD, University of California – San Francisco
Matthew Spitzer, PhD, University of California, San Francisco
All times are listed in PDT (Pacific Daylight Time).
||Basic Principles of Cancer Immunity – Abul Abbas, MD, University of California, San Francisco
||Vaccination Strategies, Identification of Neoantigens – Lisa Butterfield, PhD, Parker Institute for Cancer Immunotherapy
||The Tumor Microenvironment – Matthew Spitzer, PhD, University of California, San Francisco
||Checkpoint Blockade Therapy: Current Status, Biomarkers – TBA
|11:15 am-12:00 pm
||Next Generation Checkpoint and Combination Therapies – TBA
||Immune-Related Toxicity: Mechanisms and Management – TBA
||CAR-T Cell Therapy: Principles and Current Practices – Michelle Hermiston, MD, PhD, University of California, San Francisco
||CAR-T Cell Therapy: Next Generation CARs, Toxicities, Challenges and Prospects – Michelle Hermiston, MD, PhD, University of California, San Francisco
||Adoptive Cell Therapies: More than CAR-T – TBA
||Next Generation Strategies – Kole Roybal, PhD, University of California, San Francisco